{"id":17065,"date":"2019-10-02T00:49:52","date_gmt":"2019-10-02T04:49:52","guid":{"rendered":"https:\/\/lifeinsurance-orleans.ca\/Life-Insurance-Blog\/biologic-prescribing-authority-should-stay-with-physicians-says-survey\/"},"modified":"2019-10-02T00:49:52","modified_gmt":"2019-10-02T04:49:52","slug":"biologic-prescribing-authority-should-stay-with-physicians-says-survey","status":"publish","type":"post","link":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/2019\/10\/02\/biologic-prescribing-authority-should-stay-with-physicians-says-survey\/","title":{"rendered":"Biologic prescribing authority should stay with physicians, says survey"},"content":{"rendered":"\n
<\/div>\n

The Alliance for Safe Biologic Medicines (ASBM) has shared preliminary results from a survey asking prescribers for their views on several key policy issues surrounding the treatment category.<\/p>\n

The group took responses from a population of 575 biologic prescribers split evenly among six countries \u2014 France, Germany, Italy, Spain, Switzerland, and the United Kingdom. The largest group of prescribers, representing 47% of respondents, said they practice in a hospital setting, with the rest in academic medical centres (23%), private\/family practices (18%), multi-specialty clinics (8%), community settings (3%), and other settings (1%).<\/p>\n

When asked how much importance they place on having the sole authority to decide, along with their patients, on the most suitable biologic medicine to treat their disease, a strong 82% majority said it was \u201cvery important\u201d or \u201ccritical.\u201d That\u2019s compared to 72% of respondents in a 2013 poll where ASBM asked the same thing.<\/p>\n

The survey then asked how important it was for the biologic prescribers, in a situation wherein pharmacists have the option to dispense a biosimilar substitute, to have the authority to attach a \u201cdispense as written\u201d or \u201cdo not substitute\u201d instruction to a prescription. An 84% majority said it was \u201cvery important\u201d or \u201ccritical\u201d to be able to prevent a substitution, more than the 74% of respondents to the 2013 survey who said the same.<\/p>\n

The survey also revealed some opposing views to non-medical switching. To a question asking how comfortable they were with switching patients to a biosimilar for non-medical reasons, particularly costs, 58% said they were \u201csomewhat uncomfortable\u201d or \u201cvery uncomfortable.\u201d When the switch was initiated by a third party, however, that percentage rose to 73%.<\/p>\n

And when asked about their views on government tenders on biosimilars, 63% said that it was \u201cvery important\u201d or \u201ccritical\u201d for such tenders to be awarded to multiple suppliers. An even stronger majority of 83% said factors besides price \u2014 including reliability of supply, patient support services, manufacturer reputation \u2014 ought to be considered in national tender offers.<\/p>\n

\u201cWhile comfortable with prescribing biosimilars, Europe’s physicians want to have multiple options to choose from, so they can make the best medical decision for their patients – whether that’s the originator product, or one of its biosimilars,\u201d said Andrew Spiegel, executive director of the Global Colon Cancer Association, in a statement.<\/p>\n

\u201cCountries looking to duplicate Europe’s success with biosimilars may look to these results for guidance,\u201d added Michael Reilly, executive director of ASBM, in a statement.<\/p>\n

Read the original article at https:\/\/www.lifehealthpro.ca\/rss\/ <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The Alliance for Safe Biologic Medicines (ASBM) has shared preliminary results from a survey asking prescribers for their views on several key policy issues surrounding the treatment category. The group took responses from a...<\/p>\n","protected":false},"author":578,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[],"tags":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/posts\/17065"}],"collection":[{"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/users\/578"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/comments?post=17065"}],"version-history":[{"count":0,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/posts\/17065\/revisions"}],"wp:attachment":[{"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/media?parent=17065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/categories?post=17065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/tags?post=17065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}